Prevalence of coronary artery disease among COVID-19 patients: a systematic review and meta-analysis

Naushaba Akhtar, Bijaya Kumar Padhi, Muhammad Aaqib Shamim, Nandhni Chiruganam Gandhi, Prakisini Satapathy, Behdin Nowrouzi-Kia, Ranjit Sah, Sarvesh Rustagi, Sanghamitra Pati, Vijay Kumar Chattu
doi: https://doi.org/10.1101/2023.06.01.23290768

Abstract

Background Throughout the surge of the COVID-19 pandemic high rate of chronic diseases have been reported, including respiratory diseases and cardiovascular diseases. The prevalence of coronary artery disease has remained high throughout the COVID-19 pandemic, which also draws great concern towards it. This study seeks to provide a pooled estimate of the burden of coronary artery disease in COVID-19.

Objective To estimate the overall prevalence of coronary artery disease among COVID-19 patients

Data Sources In this systematic review and meta-analysis, an extensive literature search was conducted in PubMed, Scopus, Embase, EBSCO, Web of Science, Cochrane,Proquest and preprint servers (medRxiv, arXiv, bioRxiv, BioRN, ChiRxiv, ChiRN, and SSRN). References fo eligible articles, forward citation tracking, and expert opinion were used to identify other relevant articles. All published articles until 13 April 2023 were assessed as per the PROSPERO registration protocol (CRD42022367501).

Study Selection, Data Extraction, and Synthesis Primary studies that reported coronary artery disease among COVID-19 patients were included. The characteristics of the study and information on the number of cases of coronary artery disease were extracted from the included studies. Individual study estimates were pooled using the random intercept logistic regression model. The heterogeneity between the selected studies was assessed using the I2 statistic, tau, tau-squared, Cochran’s Q. Prediction interval was used to identify the range into which future studies are expected to fall. Subgroup analysis based on geography (continent) was done to reduce heterogeneity. Publication bias was analyzed using doi plot and LFK index. The risk of bias in the studies was assessed as per the tools proposed by the National Institute of Health.

Main outcomes The primary outcome was the pooled prevalence of coronary artery disease among COVID-19 patients within the examined population.

Results 510 records were initially retrieved from electronic databases in addition to other sources like reference screening. 33 studies with 40,064 COVID-19 patients were included for quantitative synthesis. The prevalence of coronary artery disease among COVID-19 patients was 15.24% (95% CI: 11.41% - 20.06%). The prediction interval ranged from 2.49% to 55.90%. The studies were highly heterogeneous (tau-sqaured of 0.89), and subgroup analysis significantly reduced it (test of moderators: Q = 14.77, df=2, P=.002). Europe reported the highest prevalence [21.70% (14.80% - 30.65%)], and Asia has the least prevalence [10.07% (6.55% - 15.19%)]. Meta-regression for sample size was not significant (P=.11). A symmetric doi plot and an LFK index of 0.57 revealed no evidence of publication bias or small-study effects.

Conclusion The burden of coronary artery disease has been considerable, varying with geography. and further research in this area is needed. Routine cardiac screening and assessment of COVID-19 patients can help uncover undiagnosed cases, and better optimise the management of all COVID-19 patients.

Introduction

The unprecedented challenge of the deadly COVID-19 has brought great concern for the entire healthcare system. The high incidence due to high infectivity, and high prevalence irrespective of the geographical constraints, has been a leading cause of this pandemic[1]. According to World Health Orgainzation emergency diseases dashboard 2022,the cases have reached 641,435,884 and 6621060 deaths globally till 06th December 2022. It hardly took any time to be a major public health issue, and due to the lack of available treatment, the transmission of disease also became easier.

The COVID-19 peak other co-morbidities and complications, even chronic conditions resulting from COVID-19 infection has been clearly seen. There has been various studies conducted which suggested that COVID-19 disease is a respiratory infection which can be a leading cause of other co-morbidities or other co-morbid conditions that can affect the occurrence of COVID-19 infection. As suggested in the first case report of COVID-19 infection will only affect older population with co-morbid conditions. Studies have revealed the major and most prevalent co-morbidities as cardiovascular diseases, diabetes and hypertension which has also shown positive association with SARS-CoV-2[2].

As the COVID-19 pandemic progressed with increased mortality and morbidity, their related complications were also visible. The COVID-19 pandemic, along with respiratory failure, gave rise to cardiological complications. Studies have revealed that the prevalence of cardiovascular diseases was high during the COVID-19 surge[2], [3].Researches conducted during the ICU admissions also revealed the difficulty in recovery of patients with existing cardiovascular complications like coronary artery disease, heart failure and stroke, myocardial and atherosclerosis conditions mostly[4]. One of the study conducted in China has also revealed that myocardial infarction or cardiovascular injury among patients suffering from COVID-19 increases the chances of death[5]. A recent observational study conducted at global levels has shown high coagulation and thrombotic events rates among COVID-19 patients admitted in Intensive care units[6].The consequences of heart failure and other inflammation-type responses, despite not having any prior history, have also been observed in several types of research[7]. Several studies have also indicated that the suffering of SARS CoV-2 actually doubled due to the presence of cardiovascular complications, which made life more difficult and mortality more prevalent[8]. History of heart failure or the existence of heart failure events leading to coronary artery disease may complicate the situation and make management, diagnosis and prognosis even more challenging [9], [10].

This study has highlighted complications that could result due to prevalence of coronary artery diseases among COVID-19 patients. This article is a systematic study and meta-analysis of the prevalence of coronary artery disease among patients with COVID-19. This study tries to answer the question which raised concern of many epidemiologists and physicians that whether any specific cardiovascular complications are more common in COVID-19 disease condition.

Methods

Search strategy and selection criteria

We searched seven databases: PubMed, Scopus, Web of Science, ProQuest, EMBASE, EBSCO Host, and Cochrane. The pre-print servers (medRxiv, arXiv, bioRxiv, BioRN, ChiRxiv, ChiRN and SSRN) are also included in our search strategy (Annexure 1). Furthermore, new eligible studies were extracted by carefully searching for relevant references from included papers and other suitable reviews. Using summary estimates, the primary outcome was the prevalence of coronary artery disease among COVID-19 patients. The study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) as CRD42022367501.

The search keywords included ‘coronary disease’, ‘COVID-19’, and other synonymous words. MeSH terms, and terms with an asterisk were used to identify related articles in the study title (Annexure 1). Articles were saved in Mendeley Desktop V1.19.5 software to manage citations, remove duplicates, and speed up the review process.

Data extraction and management

Two authors (NA, NCG) individually reviewed each paper. The disagreement regarding the selection of article, was resolved between two of the co-authors who conversed to build consensus and agree. Any conflict between the two leading reviewers about the eligibility of the publication, a third co-author (MAS) was consulted to assess the article and help choose whether to include the study. The reviewers discovered five articles were relevant to the main topic. Then from the eligible articles, the following information was gathered from each source article: the author’s name, the place where the study was conducted, the year of publication, the study design, the number of COVID-19 cases, cases of coronary artery disease, and other important details. A data extraction table has been prepared in a Microsoft Excel spreadsheet for further analysis.

The articles searched were reported according to the PRISMA checklist (Preferred Reporting Standard of Systematic Reviews and Meta-Analysis) to ensure scientific precision [Annexure 2]. In addition, the reviewers thoroughly read all of these publications before composing their conclusions.

Quality Assessment

The studies were independently rated by two authors using the study quality assessment tools as recommended by the National Institute of Health [Annexure 3].

Inclusion and Exclusion Criteria

All articles published until 13th of April 2023 were considered for this study. The inclusion and exclusion criteria have been given in Annexure 4.

Data Analysis

The prevalence of coronary artery disease among COVID-19 patients was calculated by dividing the number of cases of coronary artery disease by the total number of study participants. The proportions were transformed to the logarithmic scale. These were then synthesied using a random intercept logistic regression model[11] . To describe the variance amongst studies, the heterogeneity of the studies evaluated in the meta-analysis was assessed using the I2 test[12], in addition to the prediction interval[13], tau, tau-squared[14], and Cochran’s Q [15]. Heterogeneity was classified as low, moderate, and high, respectively, based on I2 values of less than 25%, 25-50%, and more than 50%. Therefore, the articles that were included in the meta-analysis were very heterogeneous. A 95% confidence interval using a random effect was used to evaluate the overall effect since we anticipated considerable between-study heterogeneity and it was seen to be higher too. P<.05 has been considered statistically significant. For the assessment of publication bias and small-study effects, we used Doi plot and the accompanying LFK index since this is a meta-analysis of proportions [13]. We performed a subgroup analysis based upon geography (continent) of study population. ‘meta’ and ‘metafor’ packages in R version 4.2.1 were utilized for conducting the meta-analysis.

Results

The systematic search was initially performed on 30th November, 2022 and repeated on 13th April, 2022. It yielded 510 articles, among which 137 duplicates were detected and removed. Two investigators (NA & NCG) independently reviewed the title/abstract screening of the 373 articles, and 311 were removed. Additionally, several articles were identified by checking the reference list of included studies, references in relevant reviews, forward citation for eligible studies, a search in Google Scholar (not a primary database for systematic reviews), and seeking the opinion of experts in the field. Full text screening of all these selected records yielded 33 studies for inclusion in systematic review and meta-analysis. [16]–[48] The PRISMA flow chart depicts the article selection and selection process [Figure 1].

Figure 1.
Figure 1.

PRISMA flow chart for included studies in systematic review and meta-analysis of prevalence of coronary artery disease among COVID-19 patients

15 of the 33 studies (45.45%) were conduced in Asia, 12 of the 33 (36.36%) in Europe, and 5 (15.15%) took place in North America. This study pooled data from several countries across the globe [48]. The baseline characteristics of all the studies has been given in Table 1. It mentions the authors, site of study, sample size, prevalence of coronary artery disease among COVID-19 patients, and other key details. This Italian study [43] reported the highest prevalence (68.92%) while the least prevalence (3.90%) was found in this study in Phillipines [44].

View this table:
Table 1:

Brief summary of the studies featured in the meta-analysis (N=33)[51]–[55]

Pooled prevalence

Amongst the 33 studies reporting on the prevalence of coronary artery disease among COVID-19 patients, we computed the pooled prevalence. It came to be 15.24% (95% CI: 11.41% - 20.06%). The prediction interval depicts the range into which future studies exploring the same outcome are expected to report. This prediction interval ranged from 2.49% to 55.90% [Figure 2].

Figure 2.
Figure 2.

Pooled prevalence forest plot of coronary artery disease among COVID-19 patients.

Heterogeneity estimation and exploration

The individual study estimates showed considerable heterogeneity with an I2 of 98.9% (95% CI: 98.7% - 99.0 %), and a tau-squared of 0.89. The Cochran’s Q is also significant with a value by Wald’s test of 4192.02 (P<.001). We used a random-effects model for the meta-analysis due to this high heterogeneity. To reduce this heterogeneity, we performed subgroup analysis and meta-regression.

Subgroup analyses based upon geographical criteria reduced heterogeneity. Dividing the studies into continents resulted in three subgroups. There is a significant difference between the three continents. This can be seen in the result of the test of moderators (Q = 14.77, df = 3, P=.002). Europe reported the highest prevalence [21.70% (14.80% - 30.65%)], and Asia has the least prevalence [10.07% (6.55% - 15.19%)]. Subgrouping also reduced the heterogeneity in the individual subgroups. Details of the subgroup analysis is given in Table 2.

View this table:
Table 2:

Subgroup analysis for pooled prevalence of coronary artery disease among COVID-19 patients – based on continent

We conducted meta-regression based upon the sample size of individual studies. This was not significant (P=.11). We constructed a bubble plot to visualize the same [Figure 3].

Figure 3.
Figure 3.

Bubble plot based on the prevalence of coronary artery disease among COVID-19 patients.

Assessment of publication bias and small-study effects

We used a Doi plot and the accompanying LFK index to assess publication bias and small study effects. The Doi plot showing individual study estimates against a folded quantile plot can be seen in Figure 4. The LFK index is 0.57. This does not suggest publication bias for estimation of prevalence of coronary artery disease among COVID-19 patients.

Figure 4.
Figure 4.

Doi plot and LFK index to assess publication bias and small-study effects for prevalence of coronary artery disease among COVID-19 patients.

Risk of Bias Assessment

The quality assessment of the findings of the included study is illustrated in the supplement file (Table 2), with majority rated to have fair quality. The assessment of quality of the included studies can be checked in the supplementary file (Annexure 2), with most studies (32 out of 33) having fair quality, while one of the studies being poor in quality. Excluding Barman et al., (2021), the only study with a poor quality slightly reduced the pooled prevalence from 15.24% (95% CI: 11.41% - 20.06%) to 14.77% (95% CI: 10.84% - 19.81%) [Annexure 5].

Discussion

This systematic review and meta-analysis results indicate that coronary artery disease is significantly associated with COVID-19. This paper gives the pooled data on prevalence of coronary artery disease complication in COVID-19 patient from the existing literature. The pooled prevalence is 15.24% (95% CI: 11.41% - 20.06%), and varies by geography. It is higher in Europe [21.70% (14.80% - 30.65%)], and lower in Asia [10.07% (6.55% - 15.19%)]. Some studies conducted in the past also reveal SARS CoV-2 as the major precursor which invades cardic cells thereby leading to cardiovasucalr conditions like myocardial inflammation and coronary artey disease[49].

Several studies show cardiovascular conditions such as coronary heart disease are associated with increased risk for severe COVID-19 and mortality, hence investigating the coronary heart disease prevalence can help stakeholders prioritize cardiovascular disease healthcare resources[48]. This study gives detailed evidence from existing literature which states the association between the two. The findings from this study can be utilized for understanding the associating between coronary artery disease and COVID-19. This study will help in clear understanding of clinical manifestations of COVID-19. This study identifies evidences from different geographical locations which gives an insight into the disease complications across the world[23]. The findings suggest a positive relationship with increase in burden of coronary artery disease among COVID-19 patients which also provides further scope for research in the similar area. There is need of more vigorous research in the similar topic and future research can be conducted for multiple cardiovascular diseases through sub-grouping of complications like myocardial infraction, atherosclerosis, thrombosis, heart failure and stroke. These can be given importance and further investigation on any of the above can also be conducted. The findings from this study provides a brief overview of the burden of coronary artery disease among COVID-19 patients. This would enable the healthcare providers, researchers and policy makers to more accurately assess the issue, identify the threats in this area and develop strategies to accomplish them.

Strengths and limitations

This systematic review and meta-analysis included studies across multiple databases of published and unpublished literature to quantify and study the prevalence of coronary artery disease among COVID-19 patients, which is the first of its kind, globally. The risk of bias in the studies have been assessed using standard tools. However, the present analysis was not devoid of limitations. There was significantly high heterogeneity among the included studies, a poor-quality study was included in the analysis, and a lack of detailed description of the disease in many studies. The substantial heterogeneity observed in the study is hypothesised due to the global nature of the data in the review with varied patient characteristics in terms of geographic location, health facilities, and other co-morbidities in the various studies.

Conclusions

This systematic review and meta-analysis examined 40,064 individuals from 33 studies and found 5333 patients with coronary artery disease in COVID-19 patients. The overall pooled prevalence of coronary artery disease in COVID-19 is 15.24%. Given the high prevalence, there is a necessity to assess cardiac health of COVID-19 patient admitted in the hospital with diagnostic methods such as ECG, 2D echo. This study highlights the need for further research in coronary artery disease and other cardiac diseases in COVID-19 patients alongwith research on evaluating cardiac biomarkers, ECG changes and other screening procedures.

Contributors

Dr Bijay kumar padhi & NA conceptualized the study and designed the protocol. NA did the PROSPERO registration. NA & NCG did the literature review, collected data and the quality assessment of the studies NA,MAS & NCG for the data. Dr Bijay kumar padhi interpreted the data. NA prepared the initial draft of the manuscript. Dr Bijay kumar padhi have reviewed, edited, and provided critical comments. Finally, NA & MAS edited the final draft and upadated the studies with the team’s amendment of critical revisions and essential suggestions. All authors had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

Declaration of Interest

None of the authors has declared any competing interests.

Funding

Indian Council of Medical Research – Senior Research Fellow [CTU/Fellowship/03/2022-ECD-II - 5th May 2022]

Data Sharing

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Data Availability

All relevant data are within the manuscript and its Supporting Information files

Supplementary material

Annexure 1: Adjusted search terms as per searched electronic databases.

Annexure 2: PRISMA checklist for reporting of the systematic review and meta-analysis Annexure 3: Quality assessment of included studies.

Annexure 4: Inclusion and Exclusion Criteria

Annexure 5: Sensitivity analysis excluding a poor quality study.

Footnotes

  • Email: nakhtar118{at}gmail.com (NA), drsanghamitra12{at}gmail.com (SP)

  • Email: bkpadhi{at}gmail.com (BKP)

  • Email: aaqibsh{at}gmail.com

  • Email: nandhni.g29{at}gmail.com

  • Email: contact{at}gces.network

  • Email: ranjitsah{at}iom.edu.np

  • Email: sarveshrustagi{at}uumail.in

References

  1. [1].
    M. Bansal, “Cardiovascular disease and COVID-19,” Diabetes Metab. Syndr. Clin. Res. Rev., vol. 14, no. 3, pp. 247–250, 2020, doi: 10.1016/j.dsx.2020.03.013.
    OpenUrlCrossRefPubMed
  2. [2].
    R. Ningthoujam and D. Khomdram, “WHO statement – ‘Older people are at highest risk from COVID-19’: Should the hypothesis be corroborated or rejected?,” Med. Hypotheses, vol. 144, 2020, doi: 10.1016/j.mehy.2020.109896.
    OpenUrlCrossRef
  3. [3].
    S. Harikrishnan et al., “Cardiological society of India position statement on COVID-19 and heart failure,” Indian Heart J., vol. 72, no. 2, pp. 75–81, 2020, doi: 10.1016/j.ihj.2020.04.012.
    OpenUrlCrossRef
  4. [4].
    B. Kumar, A. Kodliwadmath, A. Upadhyay, A. Singh, and N. N, “Apparently normal epicardial coronaries in a patient with inferior wall myocardial infraction on the background of mild coronavirus disease-2019: take a second look!,” Monaldi Arch Chest Dis, vol. 91, no. 3, 2021, doi: 10.4081/monaldi.2021.1668.
    OpenUrlCrossRef
  5. [5].
    M. J. Ahlers et al., “Characteristics and outcomes of patients presenting with acute myocardial infarction and cardiogenic shock during COVID-19,” Catheter Cardiovasc Interv, vol. 100, no. 4, pp. 568–574, Oct. 2022, doi: 10.1002/ccd.30390.
    OpenUrlCrossRef
  6. [6].
    R. Yalamanchi et al., “Cardiac intensive care unit admissions during covid-19 pandemic—single center experience,” Indian J. Crit. Care Med., vol. 24, no. 11, pp. 1103–1105, 2020, doi: 10.5005/jp-journals-10071-23660.
    OpenUrlCrossRef
  7. [7].
    Z. Wang et al., “Red blood cell distribution width: A severity indicator in patients with COVID-19,” Journal of Medical Virology, vol. 94, no. 5, pp. 2133–2138, May 2022, doi: 10.1002/jmv.27602.
    OpenUrlCrossRef
  8. [8].
    T. Abe et al., “Cardiovascular complications in COVID-19 patients with or without diabetes mellitus,” Endocrinol. Diabetes Metab., vol. 4, no. 2, 2021, doi: 10.1002/edm2.218.
    OpenUrlCrossRef
  9. [9].
    R. Choudhary, A. Kaushik, and J. B. Sharma, “COVID-19 pandemic and stent thrombosis in a post percutaneous coronary intervention patient-a case report highlighting the selection of P2Y12 inhibitor,” Cardiovasc. Diagn. Theer., vol. 10, no. 4, pp. 898–901, 2020, doi: 10.21037/cdt-20-485.
    OpenUrlCrossRef
  10. [10].
    N. Garg, B. McClafferty, D. Ramgobin, R. Golamari, R. Jain, and R. Jain, “Cardiology and COVID-19: Do we have sufficient information?,” Future Cardiol., vol. 17, no. 4, pp. 705–711, 2021, doi: 10.2217/fca-2020-0126.
    OpenUrlCrossRef
  11. [11].
    T. Stijnen, T. H. Hamza, and P. Ozdemir, “Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data.,” Statistics in medicine, vol. 29, no. 29, pp. 3046–67, Dec. 2010, doi: 10.1002/sim.4040.
    OpenUrlCrossRefPubMed
  12. [12].
    J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis.,” Statistics in medicine, vol. 21, no. 11, pp. 1539–58, Jun. 2002, doi: 10.1002/sim.1186.
    OpenUrlCrossRefPubMedWeb of Science
  13. [13].
    M. A. Shamim, P. Dwivedi, and B. K. Padhi, “Beyond the Funnel Plot: The Advantages of Doi Plots and Prediction Intervals in Meta-Analyses,” Asian Journal of Psychiatry, pp. 103550– 103550, Mar. 2023, doi: 10.1016/j.ajp.2023.103550.
    OpenUrlCrossRef
  14. [14].
    A. A. Veroniki et al., “Methods to estimate the between-study variance and its uncertainty in meta-analysis.,” Research synthesis methods, vol. 7, no. 1, pp. 55–79, Mar. 2016, doi: 10.1002/jrsm.1164.
    OpenUrlCrossRefPubMed
  15. [15].
    W. G. Cochran, “The Combination of Estimates from Different Experiments,” Biometrics, vol. 10, no. 1, pp. 101–101, Mar. 1954, doi: 10.2307/3001666.
    OpenUrlCrossRefWeb of Science
  16. [16].
    Y. Xie et al., “Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of Coronavirus Disease 2019 (COVID-19),” Circ J, vol. 84, no. 8, pp. 1277–1283, Jul. 2020, doi: 10.1253/circj.CJ-20-0348.
    OpenUrlCrossRef
  17. [17].
    N. Aladağ and R. D. Atabey, “The role of concomitant cardiovascular diseases and cardiac biomarkers for predicting mortality in critical COVID-19 patients,” Acta Cardiologica, vol. 76, no. 2, pp. 132–139, Mar. 2021, doi: 10.1080/00015385.2020.1810914.
    OpenUrlCrossRef
  18. [18].
    H. A. Barman et al., “Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease,” Coronary Artery Disease, vol. 32, no. 5, p. 359, Aug. 2021, doi: 10.1097/MCA.0000000000000914.
    OpenUrlCrossRef
  19. [19].
    E. Bruce et al., “Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19,” JCM, vol. 9, no. 8, p. 2586, Aug. 2020, doi: 10.3390/jcm9082586.
    OpenUrlCrossRef
  20. [20].
    Y. Cen et al., “Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study,” Clinical Microbiology and Infection, vol. 26, no. 9, pp. 1242–1247, Sep. 2020, doi: 10.1016/j.cmi.2020.05.041.
    OpenUrlCrossRef
  21. [21].
    N. Gupta et al., “Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India,” Monaldi Archives for Chest Disease, vol. 90, no. 4, Art. no. 4, Nov. 2020, doi: 10.4081/monaldi.2020.1507.
    OpenUrlCrossRef
  22. [22].
    J. Hewitt et al., “The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study,” The Lancet Public Health, vol. 5, no. 8, pp. e444–e451, Aug. 2020, doi: 10.1016/S2468-2667(20)30146-8.
    OpenUrlCrossRef
  23. [23].
    G. Iaccarino et al., “Age and Multimorbidity Predict Death Among COVID-19 Patients,” Hypertension, vol. 76, no. 2, pp. 366–372, Aug. 2020, doi: 10.1161/HYPERTENSIONAHA.120.15324.
    OpenUrlCrossRefPubMed
  24. [24].
    F. Lagi et al., “Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020,” Eurosurveillance, vol. 25, no. 17, p. 2000556, Apr. 2020, doi: 10.2807/1560-7917.ES.2020.25.17.2000556.
    OpenUrlCrossRef
  25. [25].
    M. E. Lendorf et al., “Characteristics and early outcomes of patients hospitalised for COVID-19 in North Zealand, Denmark,” Dan Med J, vol. 67, no. 9, p. A06200428, Aug. 2020.
    OpenUrlPubMed
  26. [26].
    J. Li, G. Xu, H. Yu, X. Peng, Y. Luo, and C. Cao, “Clinical Characteristics and Outcomes of 74 Patients With Severe or Critical COVID-19,” The American Journal of the Medical Sciences, vol. 360, no. 3, pp. 229–235, Sep. 2020, doi: 10.1016/j.amjms.2020.05.040.
    OpenUrlCrossRef
  27. [27].
    Y. Liao et al., “Clinical characteristics and prognostic factors of COVID-19 patients progression to severe: a retrospective, observational study,” Aging, vol. 12, no. 19, pp. 18853–18865, Oct. 2020, doi: 10.18632/aging.103931.
    OpenUrlCrossRef
  28. [28].
    M. K. Turagam et al., “Malignant Arrhythmias in Patients With COVID-19,” Circulation: Arrhythmia and Electrophysiology, vol. 13, no. 11, p. e008920, Nov. 2020, doi: 10.1161/CIRCEP.120.008920.
    OpenUrlCrossRef
  29. [29].
    M. G. Argenziano, et al., “Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series,” BMJ, vol. 369, p. m1996, May 2020, doi: 10.1136/bmj.m1996.
    OpenUrlAbstract/FREE Full Text
  30. [30].
    R. Chen et al., “Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China,” CHEST, vol. 158, no. 1, pp. 97–105, Jul. 2020, doi: 10.1016/j.chest.2020.04.010.
    OpenUrlCrossRefPubMed
  31. [31].
    Q. Deng et al., “Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China,” International Journal of Cardiology, vol. 311, pp. 116–121, Jul. 2020, doi: 10.1016/j.ijcard.2020.03.087.
    OpenUrlCrossRefPubMed
  32. [32].
    H. Xingwei et al., “Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients,” Chinese Journal of Cardiology, vol. 48, no. 06, Art. no. 06, Jun. 2020, doi: 10.3760/cma.j.cn112148-20200228-00137.
    OpenUrlCrossRefPubMed
  33. [33].
    C. Lodigiani et al., “Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy,” Thrombosis Research, vol. 191, pp. 9–14, Jul. 2020, doi: 10.1016/j.thromres.2020.04.024.
    OpenUrlCrossRefPubMed
  34. [34].
    S. Shi et al., “Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019,” European Heart Journal, vol. 41, no. 22, pp. 2070–2079, Jun. 2020, doi: 10.1093/eurheartj/ehaa408.
    OpenUrlCrossRefPubMed
  35. [35].
    S. Tai et al., “Association between Cardiovascular Burden and Requirement of Intensive Care among Patients with Mild COVID-19,” Cardiovascular Therapeutics, vol. 2020, p. e9059562, Aug. 2020, doi: 10.1155/2020/9059562.
    OpenUrlCrossRef
  36. [36].
    P. G. Rossi et al., “Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy,” PLOS ONE, vol. 15, no. 8, p. e0238281, Aug. 2020, doi: 10.1371/journal.pone.0238281.
    OpenUrlCrossRefPubMed
  37. [37].
    S. F. Lax et al., “Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome,” Ann Intern Med, vol. 173, no. 5, pp. 350–361, Sep. 2020, doi: 10.7326/M20-2566.
    OpenUrlCrossRef
  38. [38].
    R. M. Inciardi et al., “Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy,” European Heart Journal, vol. 41, no. 19, pp. 1821–1829, May 2020, doi: 10.1093/eurheartj/ehaa388.
    OpenUrlCrossRefPubMed
  39. [39].
    J. Zhang et al., “Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China,” Allergy, vol. 75, no. 7, pp. 1730–1741, 2020, doi: 10.1111/all.14238.
    OpenUrlCrossRefPubMed
  40. [40].
    S. Richardson et al., “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area,” JAMA, vol. 323, no. 20, pp. 2052–2059, May 2020, doi: 10.1001/jama.2020.6775.
    OpenUrlCrossRefPubMed
  41. [41].
    L. Zhang et al., “Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China,” Circulation, vol. 142, no. 2, pp. 114–128, Jul. 2020, doi: 10.1161/CIRCULATIONAHA.120.046702.
    OpenUrlCrossRefPubMed
  42. [42].
    Y. Du et al., “Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study,” Am J Respir Crit Care Med, vol. 201, no. 11, pp. 1372–1379, Jun. 2020, doi: 10.1164/rccm.202003-0543OC.
    OpenUrlCrossRefPubMed
  43. [43].
    A. Scoccia et al., “Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19,” Atherosclerosis, vol. 328, pp. 136–143, Jul. 2021, doi: 10.1016/j.atherosclerosis.2021.03.041.
    OpenUrlCrossRef
  44. [44].
    R. D. G. Jamora, M. B. Prado, V. M. M. Anlacan, M. C. C. Sy, and A. I. Espiritu, “Incidence and risk factors for stroke in patients with COVID-19 in the Philippines: An analysis of 10,881 cases,” Journal of Stroke and Cerebrovascular Diseases, vol. 31, no. 11, p. 106776, Nov. 2022, doi: 10.1016/j.jstrokecerebrovasdis.2022.106776.
    OpenUrlCrossRef
  45. [45].
    R. Bali and R. K. Calton, “Cardiovascular complications in COVID-19: A comparative study of clinical characteristics and their effect on the outcome of first wave and second wave,” Indian Heart J, vol. 73, pp. S66–S67, Dec. 2021, doi: 10.1016/j.ihj.2021.11.129.
    OpenUrlCrossRef
  46. [46].
    C. Meloche et al., “CARDIOVASCULAR DISEASE AND OUTCOMES IN CRITICALLY ILL PATIENTS WITH COVID-19: A STOP-COVID ANCILLARY,” J Am Coll Cardiol, vol. 77, no. 18, p. 3127, May 2021, doi: 10.1016/S0735-1097(21)04482-X.
    OpenUrlCrossRef
  47. [47].
    L. Slipczuk et al., “Coronary artery calcification and epicardial adipose tissue as independent predictors of mortality in COVID-19,” Int J Cardiovasc Imaging, vol. 37, no. 10, pp. 3093–3100, Oct. 2021, doi: 10.1007/s10554-021-02276-2.
    OpenUrlCrossRef
  48. [48].
    D. Prabhakaran et al., “Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study,” vol. 17, no. 1, Art. no. 1, Jun. 2022, doi: 10.5334/gh.1128.
    OpenUrlCrossRef
  49. [49].
    A. Docea et al., “A new threat from an old enemy: Re⍰emergence of coronavirus (Review),” Int J Mol Med, Mar. 2020, doi: 10.3892/ijmm.2020.4555.
    OpenUrlCrossRefPubMed
Back to top
Posted June 01, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Prevalence of coronary artery disease among COVID-19 patients: a systematic review and meta-analysis
Naushaba Akhtar, Bijaya Kumar Padhi, Muhammad Aaqib Shamim, Nandhni Chiruganam Gandhi, Prakisini Satapathy, Behdin Nowrouzi-Kia, Ranjit Sah, Sarvesh Rustagi, Sanghamitra Pati, Vijay Kumar Chattu
medRxiv 2023.06.01.23290768; doi: https://doi.org/10.1101/2023.06.01.23290768
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area